Lorna Hopcroft

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont et al. · Journal of Medicinal Chemistry · 2022 · 56 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

Cath Eberlein, Stuart C. Williamson, Lorna Hopcroft et al. · British Journal of Cancer · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacology +15

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson et al. · npj Breast Cancer · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17